NICE widens access to biologic RA treatments, but there is still a long way to go
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has U-turned on previous draft recommendations on biologic treatments for rheumatoid arthritis (RA). Two pieces of final guidance published today now give patients access to more than one TNF-inhibitor and Roche's RoActemra (tocilizumab).